English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

© 2012 The Authors. doi: 10.2340/00015555-1289 Journal Compilation © 2012 Acta Dermato-Venereologica. ISSN 0001-5555 Chronic myeloid leukaemia (CML) is the result of a fusion gene (BCR-ABL) which produces a constitutively activated tyrosine kinase (1).Tyrosine kinase inhibitors are used in the treatment of Philadelphia chromosomepositive (Ph-positive) haematological malignancies. Yet, the first generation of these drugs, including imatinib mesylate, has been associated with the development of treatment-resistant cases and drug intolerance. Improved understanding of the interaction between imatinib and its target led to the design of second-line tyrosine-kinase inhibitors, among which dasatinib and nilotinib are used in clinical practice (2, 3). Dasatinib is an oral multi-target tyrosine-kinase inhibitor, which is able to inhibit the majority of imatinibresistant BCR-ABL mutant forms, Src-family tyrosine kinases, c-Kit, ephrin-A2 receptor (EphA2R) and platelet-derived growth factor receptor-β (PDGFR-β) (4). The use of this drug has been approved for the treat ment of CML in patients resistant or intolerant to previous therapies, and Ph-positive acute lymphoid leukaemia (ALL) (5). Cutaneous side-effects have rarely been reported in the literature (6, 7). We report here a case of a paediatric patient affected by Ph-positive ALL who experienced the appearance of achromic patches on his neck and hands and complete depigmentation of his hair, eyelashes and eyebrows.

Hair Depigmentation and Vitiligo-like Lesions in a Leukaemic Paediatric Patient during Chemotherapy with Dasatinib